Home

Welcome to the SWYAPC website

The information on these pages is intended as a guide only. Whilst we endeavour to keep such information as up to date as possible, we make no claim as to its total accuracy or completeness. Information is liable to change, and such changes may not be mirrored in this site. We do not accept liability for any loss or damage resulting from use of this site or reliance on its content. External links lead to sites and pages over which we have no control, and which we cannot verify for accuracy or content. The inclusion of a link on this website should not be taken as an endorsement of the linked website, nor of the accuracy or quality of the information on such sites.

 

Updates following the March 2019 Area Prescribing Committee Meeting

Red, Amber and Green Specialist Indication

 

Red

Caplacizumab – acquired thrombotic thrombocytopenic purpura (aTTP)

Cladribine (oral) for treating relapsing-remitting multiple sclerosis (TA493)

Clomifene for IVF diagnosing and treating fertility problems

Liposomal cytarabine-daunorubicin for untreated acute myeloid leukaemia (TA552)

Ocrelizumab for treating relapsing-remitting multiple sclerosis (TA533)

Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma (TA540) advanced melanoma not previously treated with ipilimumab (TA366)

Venetoclax for treating chronic lymphocytic leukaemia (TA487)

 

Amber

Cinacalcet for all indications

Sevelamer for adult renal dialysis

 

Green Specialist Initiation

Chloral Hydrate (oral) for paediatric neurology and palliative care

 

Flash Glucose Monitoring – Update March 2019

We are currently working with diabetes specialists in West Yorkshire and Harrogate to update our policies on flash glucose monitoring, following the publication of new guidance from NHS England, and agree a single policy for all nine clinical commissioning groups.

NHS England has recently published guidance entitled “Flash Glucose Monitoring: National Arrangements for Funding of Relevant Diabetes Patients.”  The criteria outlined in the document are similar but not identical to the current policies in place across West Yorkshire and Harrogate.

The West Yorkshire and Harrogate Pharmacy Leadership Group is currently working with the diabetes specialists across West Yorkshire and Harrogate to produce a single policy in light of this national guidance.

Once this work has been completed, an amended policy will be published. Until this time, current policies are still valid.

There is also a link to our news page here if helpful

https://www.wyhpartnership.co.uk/news-and-blog/news/flash-glucose-monitoring

 

 

 

Primary Care Antimicrobial Guidelines

On 16 January 2019 the South West Yorkshire Area Prescribing Committee approved local use of the new  NICE/PHE managing common infections guidance.

This supersedes our local primary care guideline. As NICE/PHE have not completed all sections yet, we will continue to use local guidelines for those sections.

NICE/PHE – introduction to guidelines

NICE/PHE table – managing common infections (whole guideline)

 

Valproate Pregnancy Prevention Programme

The following sections include new information about valproate and pregnancy: Medicines alerts and safety issues; mental health; patient information.

 

Skin preparations (emollients)

West Yorkshire Fire & Rescue Service has produced YouTube Videos for the public and patients and one for healthcare professionals warning that skin preparations can increase the risk of a fire developing. The YouTube videos have been added to the following sections of the website for information and discussion:  Medicines Alerts and Safety Issues, Patient Information and Care Homes. There is also information on the Fire Service’s website. The MHRA has issued a press release.

 

Antimicrobial resistance

UK 5-year action plan for antimicrobial resistance 2019 to 2024 

and UK 20-year vision for antimicrobial resistance

The new plan includes a strong focus on infection prevention and control and a target to reduce UK antimicrobial use in humans by 15% by 2024.